News
Eli Lilly sues four telehealth compounding GLP-1 companies
Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss medications. Lilly filed four lawsuits on Wednesday claiming telehealth companies were misleading consumers and illegally prescribing compounded versions of its glucagon-like peptide-1 agonist drugs Mounjaro and Zepbound.
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...
Barchart on MSN2d
Eli Lilly's Quarterly Earnings Preview: What You Need to KnowWith a market cap of $775.6 billion, Eli Lilly and Company (LLY) is a global biopharmaceutical leader with leading products ...
Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ratings for the ...
Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the company and its stock ...
Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback